dalteparin has been researched along with Exanthema in 5 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Exanthema: Diseases in which skin eruptions or rashes are a prominent manifestation. Classically, six such diseases were described with similar rashes; they were numbered in the order in which they were reported. Only the fourth (Duke's disease), fifth (ERYTHEMA INFECTIOSUM), and sixth (EXANTHEMA SUBITUM) numeric designations survive as occasional synonyms in current terminology.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We describe a female patient, whose localized reaction from dalteparin was followed by a generalized rash presenting as acute generalized exanthematous pustulosis." | 7.74 | Acute generalized exanthematous pustulosis from dalteparin. ( Aberer, W; Grims, R; Komericki, P; Kränke, B, 2007) |
| " We describe a female patient, whose localized reaction from dalteparin was followed by a generalized rash presenting as acute generalized exanthematous pustulosis." | 3.74 | Acute generalized exanthematous pustulosis from dalteparin. ( Aberer, W; Grims, R; Komericki, P; Kränke, B, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Righini, M | 1 |
| Galanaud, JP | 1 |
| Guenneguez, H | 1 |
| Brisot, D | 1 |
| Diard, A | 1 |
| Faisse, P | 1 |
| Barrellier, MT | 1 |
| Hamel-Desnos, C | 1 |
| Jurus, C | 1 |
| Pichot, O | 1 |
| Martin, M | 1 |
| Mazzolai, L | 1 |
| Choquenet, C | 1 |
| Accassat, S | 1 |
| Robert-Ebadi, H | 1 |
| Carrier, M | 1 |
| Le Gal, G | 1 |
| Mermilllod, B | 1 |
| Laroche, JP | 1 |
| Bounameaux, H | 1 |
| Perrier, A | 1 |
| Kahn, SR | 1 |
| Quere, I | 1 |
| Mattioli, M | 1 |
| Fustini, E | 1 |
| Gennarini, S | 1 |
| Kim, KH | 1 |
| Lynfield, Y | 1 |
| Komericki, P | 1 |
| Grims, R | 1 |
| Kränke, B | 1 |
| Aberer, W | 1 |
| Rupec, RA | 1 |
| Boneberger, S | 1 |
| Ruzicka, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Contention Alone Versus Anticoagulation for Symptomatic Calf Vein Thrombosis Diagnosed by Ultrasonography[NCT00421538] | Phase 3 | 260 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis[NCT04981327] | Phase 3 | 1,300 participants (Anticipated) | Interventional | 2022-09-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for dalteparin and Exanthema
| Article | Year |
|---|---|
[Adverse cutaneous drug reactions].
Topics: Acneiform Eruptions; Dalteparin; Diagnosis, Differential; Drug Eruptions; Eosinophilia; ErbB Recepto | 2007 |
1 trial available for dalteparin and Exanthema
| Article | Year |
|---|---|
Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Anticoagulants; Canada; Double-Blind Method; Early Termination of Clinical Trials; Exan | 2016 |
Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Anticoagulants; Canada; Double-Blind Method; Early Termination of Clinical Trials; Exan | 2016 |
Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Anticoagulants; Canada; Double-Blind Method; Early Termination of Clinical Trials; Exan | 2016 |
Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Anticoagulants; Canada; Double-Blind Method; Early Termination of Clinical Trials; Exan | 2016 |
3 other studies available for dalteparin and Exanthema
| Article | Year |
|---|---|
Heart transplant recipient patient with COVID-19 treated with tocilizumab.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anticoagulants; Cardiomyopathy, Dilated; C | 2020 |
Enoxaparin-induced generalized exanthem.
Topics: Biopsy, Needle; Drug Eruptions; Enoxaparin; Exanthema; Female; Follow-Up Studies; Humans; Immunohist | 2003 |
Acute generalized exanthematous pustulosis from dalteparin.
Topics: Acute Disease; Anticoagulants; Dalteparin; Drug Eruptions; Exanthema; Female; Humans; Injections; Mi | 2007 |